DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION	
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
1201 Harbor Bay Parkway	11/18/2019-11/25/2019*
Alameda, CA 94502-7070 (510)337-6700 Fax:(510)337-6702	FEI NUMBER 3011769075
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Jeffrey S. Lang, Pharmacist-In-Charge	
FIRM NAME	STREET ADDRESS
One Way Drug DBA Partell Specialty Pharmacy	5835 S Eastern Ave, Ste 101
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Las Vegas, NV 89119-3031	Producer of Non-Sterile Drugs

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

OBSERVATION 1

You produced hazardous drugs without providing adequate containment, segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically,

Your firm has not demonstrated that (b) (4) and disposable germicidal wipes used by your employees to wipe down your (b) (4) hoods, equipment, and utensils between uses is capable of deactivating hazardous drug substances. The (b) (4) noods, equipment, and utensils are non-dedicated and are used for producing hazardous and non-hazardous drug substances.

For example, on 11/18/2019 we observed dispensing/production of the following hazardous drug; (b) (4) g of Progesterone (b) (4) (b) (4) , Lot# (b) (4) , Exp. 3/30/22 used to compound Progesterone 130 mg Capsules, Lot# 20191118@54, followed by dispensing of the following non-hazardous drug in the same (b) (4) hood, (b) (4) g of Naltrexone Hydrochloride, USP (b) (4), Lot# (b) (4) , Exp 1/31/22, used to compound Naltrexone IR (Ascorbic Acid) 4.5 mg Capsules.

*DATES OF INSPECTION

SEE REVERSE OF THIS PAGE EMPLOYEE(S) SIGNATURE

Zachary L Stamm, Investigator Jolanna A Norton, Generic Drug User Fee Amendments (GDUFA)



DATE ISSUED 11/25/2019

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

INSPECTIONAL OBSERVATIONS

PAGE 1 of 2 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER 1201 Harbor Bay Parkway 11/18/2019-11/25/2019* FEI NUMBER Alameda, CA 94502-7070 3011769075 (510) 337-6700 Fax: (510) 337-6702 NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Jeffrey S. Lang, Pharmacist-In-Charge FIRM NAME STREET ADDRESS One Way Drug DBA Partell Specialty 5835 S Eastern Ave, Ste 101 Pharmacy CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED Las Vegas, NV 89119-3031 Producer of Non-Sterile Drugs 11/18/2019(Mon), 11/19/2019(Tue), 11/20/2019(Wed), 11/21/2019(Thu), 11/22/2019(Fri), 11/25/2019(Mon)

SEE REVERSE OF THIS PAGE EMPLOYEE(S) SIGNATURE

Zachary L Stamm, Investigator Jolanna A Norton, Generic Drug User Fee Amendments (GDUFA)



DATE ISSUED 11/25/2019

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

INSPECTIONAL OBSERVATIONS

PAGE 2 of 2 PAGES